S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Fed's Shocking New Plan to Control Your Money (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Fed's Shocking New Plan to Control Your Money (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Fed's Shocking New Plan to Control Your Money (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Fed's Shocking New Plan to Control Your Money (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Fed's Shocking New Plan to Control Your Money (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Fed's Shocking New Plan to Control Your Money (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Fed's Shocking New Plan to Control Your Money (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Fed's Shocking New Plan to Control Your Money (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
NYSE:AMRX

Amneal Pharmaceuticals - AMRX Stock Forecast, Price & News

$1.29
-0.04 (-3.01%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.26
$1.35
50-Day Range
$1.29
$2.70
52-Week Range
$1.26
$4.60
Volume
1.16 million shs
Average Volume
1.11 million shs
Market Capitalization
$391.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.67

Amneal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
184.2% Upside
$3.67 Price Target
Short Interest
Bearish
8.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.51
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
2.00%
From $0.50 to $0.51 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

389th out of 995 stocks

Pharmaceutical Preparations Industry

176th out of 482 stocks


AMRX stock logo

About Amneal Pharmaceuticals (NYSE:AMRX) Stock

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMRX Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Q4 2022 Amneal Pharmaceuticals Inc Earnings Call
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Amneal Pharmaceuticals
Amneal Pharmaceuticals: Risk Still Persists
Amneal to Participate at Upcoming Investor Conferences
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMRX Company Calendar

Last Earnings
3/02/2023
Today
3/27/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
7,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.67
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+184.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-129,990,000.00
Pretax Margin
-11.22%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$1.37 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
222,309,000
Market Cap
$391.67 million
Optionable
Optionable
Beta
1.37

Key Executives

  • Chintu Patel
    Co-Chief Executive Officer & Director
  • Chirag K. PatelChirag K. Patel
    President & Co-Chief Executive Officer & Director
  • Andrew S. Boyer
    Executive Vice President-Commercial Operations
  • Anastasios G. Konidaris
    Executive VP, Chief Financial & Accounting Officer
  • Nikita ShahNikita Shah
    Chief Human Resources Officer & Executive VP













AMRX Stock - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price forecast for 2023?

3 equities research analysts have issued 12 month price targets for Amneal Pharmaceuticals' stock. Their AMRX share price forecasts range from $3.00 to $4.00. On average, they predict the company's share price to reach $3.67 in the next twelve months. This suggests a possible upside of 184.2% from the stock's current price.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2023?

Amneal Pharmaceuticals' stock was trading at $1.99 on January 1st, 2023. Since then, AMRX shares have decreased by 35.2% and is now trading at $1.29.
View the best growth stocks for 2023 here
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a drop in short interest during the month of February. As of February 28th, there was short interest totaling 7,120,000 shares, a drop of 11.7% from the February 13th total of 8,060,000 shares. Based on an average daily volume of 1,290,000 shares, the days-to-cover ratio is currently 5.5 days. Currently, 7.2% of the company's shares are sold short.
View Amneal Pharmaceuticals' Short Interest
.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our AMRX earnings forecast
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) issued its earnings results on Thursday, March, 2nd. The company reported $0.21 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.02. The business earned $609.80 million during the quarter, compared to the consensus estimate of $579.93 million. Amneal Pharmaceuticals had a negative net margin of 5.88% and a positive trailing twelve-month return on equity of 76.11%. The company's quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.16 EPS.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY23 earnings guidance on Thursday, March, 2nd. The company provided earnings per share (EPS) guidance of $0.40-0.50 for the period, compared to the consensus EPS estimate of $0.77. The company issued revenue guidance of $2.25-2.35 billion, compared to the consensus revenue estimate of $2.31 billion.

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.65%), Morgan Stanley (1.39%), Norges Bank (0.89%), AQR Capital Management LLC (0.70%), Geode Capital Management LLC (0.60%) and Allspring Global Investments Holdings LLC (0.52%). Insiders that own company stock include Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $1.29.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $391.67 million and generates $2.21 billion in revenue each year. The company earns $-129,990,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

The company employs 7,600 workers across the globe.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.

This page (NYSE:AMRX) was last updated on 3/28/2023 by MarketBeat.com Staff